Christian Kanstrup

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

The best way to predict the future is to co-create it. KRING® is a family of impact funds. We co-create new sustainable ventures together with bold entrepreneurs and leading corporate players who are dedicated to building a positive future. Over the years we have co-created and launched more than 20 companies. Some are alive. Some we have killed. Some are acquired. Today our efforts are fully focused on the sustainable development goals. We have our own investment fund that supports our Speedbooting innovation process and enables us to execute fast and focused with co-founders and strategic partners. Through the building of many new ventures and digital companies, we have adopted and adjusted methodologies of entrepreneurship, innovation and co-creation to systematically build new impact ventures together with co-founders and corporates - and help them succeed, grow and create impact. We are committed to using all our efforts on venture building with a strong focus on the SDG agenda, initially Health & Wellbeing (SDG 3) and on Energy (SDG 7). If you are a potential co-founder with a passion for Energy or Health & Wellbeing – let’s talk.

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mothers milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!